Pharmanutra SpA
MIL:PHN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Pharmanutra SpA
Accounts Receivables
Pharmanutra SpA
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pharmanutra SpA
MIL:PHN
|
Accounts Receivables
€26.9m
|
CAGR 3-Years
5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Intercos SpA
MIL:ICOS
|
Accounts Receivables
€143.3m
|
CAGR 3-Years
0%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Enervit SpA
MIL:ENV
|
Accounts Receivables
€22.6m
|
CAGR 3-Years
21%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
Pharmanutra SpA
Glance View
Pharmanutra SpA develops nutraceutical products and medical devices. The company is headquartered in Pisa, Pisa. The company went IPO on 2017-07-18. The firm develops nutraceutical products and medical devices. The company focuses on studying and producing formulations that are backed up in scientific research. The company is able to cover all stages of the development of a product, from its design, formulation and registration to its marketing, distribution and training of its commercial representatives. The firm offers Gestalys DHA, a nutritional supplement; Cetilar, a massage coadiuvant, improves and brings relief to joints affected by osteoarthritis; Cetilar patch, a transdermic patch containing a concentrated formulation of cetylated fatty acids (CFA) esters; SiderAL Forte; CardioSiderAL; SiderAL Folico; SiderAL; Bonecal and Novomega, among others.
See Also
What is Pharmanutra SpA's Accounts Receivables?
Accounts Receivables
26.9m
EUR
Based on the financial report for Sep 30, 2025, Pharmanutra SpA's Accounts Receivables amounts to 26.9m EUR.
What is Pharmanutra SpA's Accounts Receivables growth rate?
Accounts Receivables CAGR 3Y
5%
Over the last year, the Accounts Receivables growth was 10%. The average annual Accounts Receivables growth rates for Pharmanutra SpA have been 5% over the past three years .
